Clinical translation of 177Lu-labeled PSMA-617: Initial experience in prostate cancer patients
dc.contributor.author | Das, T. | |
dc.contributor.author | Guleria, M. | |
dc.contributor.author | Parab, A. | |
dc.contributor.author | Kale, C. | |
dc.contributor.author | Shah, H. | |
dc.contributor.author | Sarma, H. D. | |
dc.contributor.author | Lele, V. R. | |
dc.contributor.author | Banerjee, S. | |
dc.date.accessioned | 2016-10-28T08:58:02Z | |
dc.date.available | 2016-10-28T08:58:02Z | |
dc.date.issued | 2016 | |
dc.description.division | RPhCS;RB&HSD | en |
dc.format.extent | 5202 bytes | |
dc.format.mimetype | text/html | |
dc.identifier.source | Nuclear Medicine and Biology, 2016. Vol. 43 (5): pp. 296-302 | en |
dc.identifier.uri | http://hdl.handle.net/123456789/13590 | |
dc.language.iso | en | en |
dc.subject | PSMA-617 | en |
dc.subject | 177Lu | en |
dc.subject | Prostate cancer | en |
dc.subject | Theranostic application | en |
dc.subject | Targeted radionuclide therapy | en |
dc.title | Clinical translation of 177Lu-labeled PSMA-617: Initial experience in prostate cancer patients | en |
dc.type | Article | en |